45 citations,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
37 citations,
May 2004 in “Multiple Sclerosis Journal” The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
The new treatment regimen was effective in promoting significant hair growth in all 15 male patients with androgenic alopecia.
December 2021 in “International Journal of Biology Pharmacy and Allied Sciences” Autoimmune diseases cause the immune system to attack the body, and management varies as some are curable and others are not.
January 2022 in “International Journal of Biology Pharmacy and Allied Sciences” Autoimmune diseases cause the immune system to attack the body, and management varies as some are curable and others are not.
6 citations,
April 2022 in “Biomedicine & pharmacotherapy” Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
25 citations,
May 2017 in “InTech eBooks” Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.
20 citations,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
253 citations,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
18 citations,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.